S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias

SINGAPORE, Nov. 27 /PRNewswire/ -- S*BIO Pte Ltd today announced the expansion of its proprietary pipeline, with its third development candidate, SB1317. This is a novel orally-available small molecule compound targeted for the treatment of acute leukemias. SB1317 is designed to selectively ...

Low micro-RNA level linked to high gene activity in AML

...tions in two genes in the leukemic cells: NPM1 and flt3 (pronounced Flit-3). The pattern of microRNA m...l gene. Furthermore, 26 of the 85 patients had flt3 mutations. These cases also had high levels of a m...igh levels of miR-155 were closely associated with flt3 mutations, they were independent of the mutation (...

Sorafenib Slows Growth of Some Leukemias

...ve the drug to mice with leukemia cells with known flt3 mutations and to leukemia patients with and without the flt3 mutation. Sorafenib slowed growth and induced cell death in the flt3 mutant leukemia cells and increased survival of th...

Kidney cancer drug attacks a major type of acute myeloid leukemia

...ease. After in vitro tests showed that sorafenib inhibited the growth of flt3 mutant leukemia cell colonies, the research team tested the medication in a...ly results of new therapies under development that more narrowly target the flt3 gene. Andreeff says the drug's ability to hit multiple kinases probably acc...

S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders

... models of hematological malignancies SB1317, a novel potent inhibitor of flt3 kinase and CDKs 1, 2 and 9, demonstrated therapeutic potential for the treatment of hematological malignancies. flt3 is the most common mutated gene in acute myeloid leukemia (AML), and CDK1...

FLT3 in Medical Technology

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

...lapsed acute myelogenous leukemia (AML) expressing flt3 activating mutations. The study was designed to s...nt inhibitor of several tyrosine kinases including flt3 and a Janus kinase (JAK2). In leukemic cells, lestaurtinib inhibits flt3 activity and induces cell death (apoptosis). In my...

Xanthus Presents Novel Approach for Autoimmune Disease Reversal with Symadex

... Symadex (formerly C-1311) is the lead compound from a new series of agents, the imidazoacridinones, which have been shown to be potent and selective flt3 receptor tyrosine kinase inhibitors in vitro. Symadex is currently in Phase 2 clinical trials in oncology indications. Xanthus is also exploring the u...

FLT3 in Biological News

Washington University scientists first to sequence genome of cancer patient

... toward cancer, and then one by one, the other genetic alterations were acquired, with each contributing something to the cancer. One mutation, in the flt3 gene, was not present in all of the tumor cells, and they suspect that it was the last one to occur. "The final mutation may represent a tipping point...

Dendritic cells offer new therapeutic target for drugs to treat MS and other autoimmune disease

...foreign invaders to soldiering T-cells. "Someday, using a drug to block flt3 gene signaling could stop dendritic cells from triggering harmful responses...ound called CEP-701, already known to block actions of the growth-promoting flt3 gene, on human dendritic cells and in mice engineered to mimic multiple scl...

FLT3 in Biological Technology

Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer

...istration filing of Gleevec(TM) in Ph+ adult acute lymphoblastic leukemia (ALL) and, as global clinical project leader, successfully brought the first flt3 kinase inhibitor PKC412 (Midostaurin) to Phase 3 in acute myelogenous leukemia (AML). Earlier in her career at Novartis, Dr. Cohen was responsible for...